NCT06125834View on ClinicalTrials.gov

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

May 31, 2026

Conditions
Advanced Breast CancerObjective Response RateTrastuzumab Emtansine
Interventions
DRUG

Trastuzumab Emtansine (T-DM1)

Enrolled patients will receive Trastuzumab Emtansine (T-DM1) treatment (3.6mg/kg, d1/21, IVD) until progressive diseases or intolerable adverse effects occurs.

Trial Locations (1)

Unknown

RECRUITING

JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER